Follow us on Twitter
twitter icon@FreshPatents

Leukemia patents


This page is updated frequently with new Leukemia-related patent applications.

new patent Method of treating and reducing the risk of acute myelogenous leukemia
The present invention relates to methods and compositions for treating and reducing the risk of acute myelogenous leukemia (aml). In particular, the invention provides methods for identifying novel treatments for aml based on reproducible and detectable changes in amli-eto acetylation.
Memorial Sloan-kettering Cancer Center

new patent Dual targeting antisense oligonucleotides as apoptotic inhibtor therapeutic compostions and methods for their use in the treatment of cancer
Provided herein are compositions, method and uses for modulating iap activity or for the treatment of cancer. The compositions comprise dual-targeting antisense oligonucleotides (daso) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of one of more of birc6, ciap1 or survivin.

new patent Enhancement of allogeneic hematopoietic stem cell transplantation
Methods and compositions are provided to augment the conversion of mixed hematopoietic cell chimerism to complete donor cell chimerism following allogeneic hematopoietic cell transplantation (hct), where such transplantation may be utilized for treatment of cancer such as leukemia and lymphoma or for other conditions requiring reconstitution of the hematopoietic system, e.g. Treatment of anemias, thalassemias, autoimmune conditions, and the like.
The Board Of Trustees Of The Leland Stanford Junior University

Anti-metalloprotease antibody for diagnosis and treatment of cancers
Expression of proteolytically active, high molecular weight adam protease is relatively increased in tumour cells that also express the putative tumour stem cell marker cd133. An antibody or antibody fragment such as 8c7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight adam10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma..
Ludwig Institute For Cancer Research Ltd

Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
(e) adjusting the dose of the inhibitor of the bcr-abl tyrosine kinase or a pharmaceutically acceptable salt thereof applied to the individual patients from said patient population and, optionally, future patients suffering from a ph+ leukemia in a manner that a cmin is achieved in each single patient equal to or higher than the cmin threshold obtained under step (d).. .

Antiproliferative compounds and methods of use thereof
Compounds of formula i for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds.
Celgene Corporation

Compositions and methods for the detection diagnosis and therapy of hematological malignancies
Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, b cell leukemias, lymphomas and multiple myelomas. Disclosed are compositions, methods and kits for eliciting immune and t cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal.
Corixa Corporation

Prognostic and diagnostic kits and herbal therapies for treating skin conditions, autoimmune diseases, inflammatory ailments and cancer
A treatment regimen for psoriasis, eczema or other skin ailment, inflammation, autoimmune disease, leukemia, melanoma or other cancer includes administering to a patient a known or discovered treatment regimen along with periodic doses of an herbal combination including sheng di huang, da huang or jin yin hua or combinations thereof.. .
Sirbal Ltd.

Prognostic and diagnostic methods and herbal therapies for treating skin conditions, autoimmune diseases, inflammatory ailments and cancer
A treatment regimen for psoriasis, eczema or other skin ailment, inflammation, autoimmune disease, leukemia, melanoma or other cancer includes administering to a patient a known or discovered treatment regimen along with periodic doses of an herbal combination including sheng di huang, da huang or jin yin hua or combinations thereof.. .
Sirbal Ltd.

Chemical compounds
Provided are a series of novel pyridine or pyrimidine derivatives which inhibit cdk9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large b cell lymphoma, burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer..
Astrazeneca Ab

Combination therapy comprising an inhibitor of jak, cdk, and pim

The present invention relates to a pharmaceutical combination which comprises (a) a jak inhibitor compound, (b) a cdk inhibitor, and (c) a pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.. .
Novartis Ag

Uses of paralog-selective inhibitors of gsk3 kinases

The present disclosure provides methods of using gsk3α-selective inhibitors for treating fragile x syndrome, attention deficit hyperactivity disorder (adhd), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (aml), autism, and psychiatric disorder. The gsk3α-selective inhibitors include compounds of formula i-a.
Massachusetts Institute Of Technology

Blood-based biomarker for cancer

A blood-based biomarker for cancer includes a specific amino acid group of at least seven amino acids. The at least seven amino acids include histidine, isoleucine, leucine, methionine, tryptophan, valine, and tyrosine.
J-pharma Co., Ltd.

Method for diagnosing, quantifying, treating, monitoring or evaluating conditions, diseases or disorders associated with human papilloma virus (hpv) infection

A method of diagnosing, quantifying, treating, monitoring or evaluating a condition in a subject is provided. The method comprises obtaining a sample from the subject, detecting and determining the presence or quantity of one or more than one human papilloma virus (hpv) in the sample, wherein the presence or quantity of the one or more than one hpv is indicative of the presence of the condition in the subject or an increased likelihood of the subject for developing the condition when compared to a control.

Fc-enhanced anti-wt1/hla antibody

The present disclosure relates to an anti-wt-1/hla/a2 antibody with enhanced antibody dependent cell-mediated cytotoxicity (adcc) function due to altered fc glycosylation. The antibody, which has reduced fucose and/or galactose, was compared to its normally glycosylated counterpart in binding assays, in vitro adcc assays, and mesothelioma and leukemia therapeutic models and pharmacokinetic studies in mice.
Eureka Therapeutics, Inc.

Methods and compositions for eradicating leukemic cells

The disclosure relates to compositions, methods, and kits comprising glycyrrhetinic acid derivatives for selectively eradicating leukemic cells in a population or subject, and related methods of treating acute myeloid leukemia, and promoting survival of acute myeloid leukemia patients.. .
The General Hospital Corporation

Anti-cd33 antibodies and methods for treatment of acute myeloid leukemia using the same

The present invention relates to antibodies that bind cd33. More particularly, the invention relates to anti-cd33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications.
Immunogen Inc.

Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment

A method of treating a disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting a non-syngeneic cell or tissue graft to the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of cells comprising non-graft versus host (gvhd) inducing anti-third party cells having a central memory t-lymphocyte (tcm) phenotype, the cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, and further wherein the cells are either: (i) non-syngeneic with both the subject and the graft; or (ii) non-syngeneic with the graft and syngeneic with the subject, thereby treating the subject..
Yeda Research And Development Co. Ltd.

Methods and compounds for modulating the secretion or expression of adhesion proteins or angiopoietins of cells

This invention provides methods, processes, compounds and compositions for modulating the gene expression or secretion of adhesion proteins, angiopoietins or their receptors to cure diseases, for anti-angiogenesis and for treating parasites, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, myosin, vitronectin, collagen, laminin, glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, cd 54, cam, elastin and fak; wherein the angiopoietins comprise angiopoietin 1, angiopoietin 2, angiopoietin 3, angiopoietin 4, angiopoietin 5, angiopoietin 6, angiopoietin 7, angiopoietin-like 1, angiopoietin-like 2, angiopoietin-like 3, angiopoietin-like 4, angiopoietin-like 5, angiopoietin-like 6, and angiopoietin-like 7; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, cns cancer, melanoma cancer, renal cancer, cervical cancer, esophageal cancer, testicular cancer, spleenic cancer, kidney cancer, lymphatic cancer, pancreas cancer, stomach cancer and thyroid cancer.. .
Pacific Arrow Limited

Methods of treating acute t cell leukemia

The present invention is directed to methods of treating t-cell acute lymphoblastic leukemia. This method involves selecting a subject having t-cell acute lymphoblastic leukemia and administering, to the selected subject, a therapeutic agent that inhibits cxcr4-cxcl12 signaling at a dosage effective to treat the t-cell acute lymphoblastic leukemia in the subject.
New York University

G-protein coupled receptor-associated diagnostics and therapeutics for b-cell chronic lymphocytic leukemia

The disclosure provides diagnostic and therapeutic agents for chronic lymphocytic leukemia (cll). Further provided are biomarkers and a biomarker panel comprising g-protein coupled receptors (gpcrs) specifically expressed by cll cells.
The Regents Of The University Of California

Anti-toso chimeric antigen receptor and its use

In a first aspect, the present invention relates to genetically modified t-cells having a chimeric antigen receptor (car) in a method for adoptive cell therapy for treating toso+ cancer, like b-cell leukemia/lymphoma, in a subject in need thereof. In particular, the present invention relates to a genetically engineered t-cell containing and expressing a specific chimeric antigen receptor being toxic to toso+ cancer cells while being less toxic or non-toxic to toso+ non-cancer cells, in particular, being non-toxic to normal b cells and its precursors.
Universitaet Zu Koeln

Compositions and methods of use for therapeutic antibodies

The present invention relates to antibodies that specifically bind to the baff receptor (baffr). The invention more specifically relates to specific antibodies that are baffr antagonists with in vivo b cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting b cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas..
Novartis Ag

Benzamide and nicotinamide compounds and methods of using same

The present disclosure provides benzamide and nicotinamide compounds and pharmaceutical uses of the compounds. The compounds can be used to treat, for example, cancers such hematopoietic cancers (e.g., leukemia).
Oncotartis, Inc.

Drug formulations

The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives.
Astex Pharmaceuticals, Inc.

Treatment of neurological disorders

Provided herein is technology relating to treatment of neurological disorders and particularly, but not exclusively, to methods and compositions for treating neurological disorders caused by aberrant and/or dysregulated expression and/or activity of down syndrome cell adhesion molecule (dscam) with agents that modulate physiological components associated with the functions and/or dysfunctions of dscam, e.g., physiological components that can be modulated to counteract aberrant dscam expression and/or activity such as abelson murine leukemia viral oncogene homolog 1 kinase.. .
The Regents Of The University Of Michigan

Epigenetic stem cell commitment-associated signature

Methods for determining the prognosis of a subject having acute myeloid leukemia (aml) as well as methods of treating aml subjects depending on prognosis.. .
Albert Einstein College Of Medicine, Inc.

Compositions and methods for treatment of hematological malignancies

Use of a chimeric protein selected from the group consisting of ctla4-fasl and cd40-fasl proteins for treatment of lymphoma and/or a multiple myeloma and/or a leukemia as described herein, and pharmaceutical compositions and methods of treatment thereof.. .
Hadasit Medical Research Service And Development Co. Ltd.

Quantification expression level of wt1 mrna

A method for quantifying the expression level of human wt1 mrna conveniently, in a short period of time, and with high sensitivity is provided. The method can be used for diagnosing cancer, such as leukemia and solid cancer, or for determining when to perform bone marrow transplantation.
Otsuka Pharmaceutical Co., Ltd.

Baff selective binding compounds and related methods

The present invention relates to peptide antagonists that bind with high specificity and affinity to b-lymphocyte stimulator (“baff”), thereby antagonizing baff receptor (“baff-r”) signaling. The invention more specifically relates to vnar single chain antibodies derived from nurse shark that bind to baff, baff antagonist compounds and compositions comprising a baff specific vnar binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo b cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete b cells, such as in autoimmune diseases including systemic lupus erythematosus (sle), rheumatoid arthritis (ra) or multiple sclerosis (ms), and in certain hematological cancers, including lymphomas, leukemias and myelomas..
Ossianix, Inc.

Heterocyclic compounds and their uses

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Amgen Inc.

Leukemia topics:
  • Myelogenous
  • Myelogenous Leukemia
  • Proliferative
  • Autoimmune
  • Stem Cells
  • Breast Cancer
  • Rheumatoid Arthritis
  • Myeloid Leukemia
  • Acute Myelogenous Leukemia
  • Lymphocytic
  • Chronic Lymphocytic Leukemia
  • Lymphocytic Leukemia
  • Epigenetic
  • Multiple Myeloma
  • Polyphenol

  • Follow us on Twitter
    twitter icon@FreshPatents


    This listing is a sample listing of patent applications related to Leukemia for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukemia with additional patents listed. Browse our RSS directory or Search for other possible listings.


    file didn't exist2606

    478890 - 0 - 53